| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$102 ) |
| | 2023 | 2022 | EIRGEN PHARMA LIMITED | WESTSIDE BUSINESS PARK | WATERFORD | | | | IRL | R01FD007590 | A Bioequivalence Study of Two Different Formulations of Chlorambucil in Beagle Dogs | 000 | 1 | FDA | 5/12/2023 | -$102 |
| | 2023 | 2022 | EIRGEN PHARMA LIMITED | WESTSIDE BUSINESS PARK | WATERFORD | | | | IRL | R01FD007590 | A Bioequivalence Study of Two Different Formulations of Chlorambucil in Beagle Dogs | 001 | 1 | FDA | 8/14/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $250,000 ) |
| | 2022 | 2022 | EIRGEN PHARMA LIMITED | WESTSIDE BUSINESS PARK | WATERFORD | MUNSTER | | | IRL | R01FD007590 | A Bioequivalence Study of Two Different Formulations of Chlorambucil in Beagle Dogs | 000 | 1 | FDA | 6/3/2022 | $250,000 |
|
|
